Seeking Alpha

Prohost Biotech

View as an RSS Feed
View Prohost Biotech's Comments BY TICKER:
Latest  |  Highest rated
  • Organovo: Love The Technology, Like The Company, But Wait To Buy The Stock [View article]
    Great article and many good answers - all about a great company. Science is improving at the speed of light and a company expected to help large and small pharmaceutical and biotechnology firms speed their drug development and save ton of money, we believe, could be able to accomplish the same for itself, probably on a faster and less expensive scale. The future is nearing and many biotech firms achieved what made us live the future. Computer is the big helper, especially when used by genius minds who are not afraid to cross the border between now and what's supposed to be happening 14 years later.
    The fast emergence of the Internet is the best example and many achievements in biology, like the Human Genome Project, for example, which was perceived by scientists as fiction was completed in a few years, At the time, this great project cost a few billion dollars. Now, sequencing the whole genome takes a few days and might cost $1000. Thanks for the article and the great comments.
    Nov 15 05:13 PM | 1 Like Like |Link to Comment
  • Geron's Promising News Poses No Threat To Incyte [View article]
    We wait for the ASH presentation. We hope we would know more about where is the drug right now and what the developers strategy and plans regarding the next steps. We cannot jump now on the band wagon without knowing which road it is taking towards the finish line. The early results are promising. But learning from history, investing is no gambling and early results are in cases misleading most probably because what we don't know is a lot more than the small early trials might acknowledge us. If this product would make to the market, it will be a great achievement in cancer in general. We hope it will succeed.
    Nov 8 05:03 PM | 1 Like Like |Link to Comment
  • Immunogen: Opinions Are Being Expressed. Here Is Our View [View article]
    Hi Bionysus

    You comment is correct and the infection and toxicity (a word that some critics love to use because it frightens people) have nothing to do with the CAD structure, but with the selected target. Many blockbuster drugs that aim at treating much less severe diseases such as arthritis and crohn's disease cause infection, including TB because of the target, which is TNF. You got it right.
    Nov 6 09:44 PM | Likes Like |Link to Comment
  • The Time Has Come For Valuing ImmunoGen Technology And Pipeline Products [View article]
    Hi. Thanks for your reply and question. You are talking about cancer therapeutic vaccines, or immunotherapy for cancer, which have been difficult to create, but, like the antisense technology, are improving on the road towards their use as therapeutics. Although we believe that immunotherapy is much required and will succeed, their uses for a long years to come, if approved, will be part of treatments with targeted drugs, especially those that have excellent efficacy with less side effects. ImmunoGen and Seattle genetics are on top of the list of the firms that created safer and more effective targeted cancer treatments through their antibody drug conjugate technologies.
    Oct 28 01:28 PM | 1 Like Like |Link to Comment
  • Agenus And Glaxo: Sizing Up The Potential For The RTS,S Malaria Vaccine [View article]
    Thanks for the excellent article. It said it all about malaria and the difficult path for vaccination aimed at protecting against the horrible complication of the disease. The explication in the article of the role the first promising vaccine is expected to play among other measures aimed at protecting and preventing against malaria is extremely useful.
    Oct 10 09:24 AM | 3 Likes Like |Link to Comment
  • Sarepta Therapeutics: A Bigger Cake Outweighs A Lower Chance For A Party [View article]
    How many boys have been treated with SRPT drug? What Phase of trial these boys have reached to date? Did Prosensa drug have statistically significant efficacy in Phase 2 trials? What was the number treated in the trial where Prosensa's drug disapersen has achieved the promising statistically significant results? These are just questions we believe investors can make a better judgment knowing the answers to them. At the end, everybody is entitled to his own opinion. There is no reason for the fights and the insults.
    Sep 25 08:17 PM | Likes Like |Link to Comment
  • Agenus Offers An Investment Opportunity [View article]
    Yes. the results are very encouraging and bring hope to the patients, their physicians, the company's scientists behind the vaccine and Agenus' shareholders. Until now, clinical trial results are demonstrating that Prophage Series G-100 is safe and effective against a brain cancer that has yet to succumb to a treatment. Now we have to continue hoping that the regulators get excited about the results and guide Agenus, regardless of its size, to get the vaccine to cross the final bridge into the market. Hopeless people on the other side of the bridge, are anxiously waiting to be saved.
    Sep 17 09:06 PM | Likes Like |Link to Comment
  • Agenus Offers An Investment Opportunity [View article]
    Investors have to proceed with caution anyway as long as they are dealing with Wall Street democracy. However, common sense mixed with facts dictates situations where extra-cautious investors keep missing. Our statistics from our Newsletter readers demonstrate that many investors have missed stocks that rallied from under $15 to over $120 because of their caution. They missed opportunities provided by PCYC, AMGN, VRTX, REGN and plenty of other small and medium size firms whose stocks have quadrupled or more in the past one and two years. Indeed, caution is important but should also be based on studies and following up on the firms from a near distance, and direct communication rather from far away. One cannot blindly believe all that's posted on the Internet. Due diligence yes, should be made before deciding to express extreme caution based on past history in one area of the firms' lives.
    Sep 12 02:25 PM | 2 Likes Like |Link to Comment
  • Agenus Offers An Investment Opportunity [View article]

    Thanks for the observation, which is correct. As a matter of fact, we did mention herpV as a genital herpes vaccine in the beginning, as we were mentioning the upcoming catalysts. We wrote, "Phase 2 data for HerpV, Agenus'QS-21 Stimulon containing investigational therapeutic vaccine for genital herpes, during the fourth quarter of 2013." the mistake was made as we tried and meant to mention the fact that unlike the HPV vaccines on the market, HerpV is therapeutic, not preventive." So, the misleading statement happened in this part and we thank you for clarification, which was really necessary and important.'
    Sep 8 02:20 PM | Likes Like |Link to Comment
  • Agenus: Assessing Stock Prospects After MAGE A-3 Cancer Vaccine Misses Primary Endpoint In Melanoma [View article]
    Alp. We are curious to know why cancer vaccine is a hype? Are cancer immuno-therapeutics that have demonstrated safety and superior efficacy in cancer considered hype also? If so, can you explain? Unless your remark is based on previous failures of therapeutic vaccines. If this is the reason, then it is invalid as we know now much better about the immune system, its cells and antibodies, the antigen used and the adjuvant added more than any other time in the past. The science and knowledge behind the development of immuno-stimulants, modulators and other facts are solid and validated. This is true unless something that you know that scientists don't. In this case we would love to know it and we will appreciate it.
    Sep 5 04:40 PM | 7 Likes Like |Link to Comment
  • Yes, Gilead Did It Again [View article]
    We will soon. Probably following the long weekend that we hope yo will find calm in it.
    Aug 31 02:38 PM | Likes Like |Link to Comment
  • Yes, Gilead Did It Again [View article]
    We did and we will write about it. Thanks
    Aug 31 02:36 PM | Likes Like |Link to Comment
  • Yes, Gilead Did It Again [View article]
    Thank you and enjoy the long weekend.
    Aug 31 02:35 PM | Likes Like |Link to Comment
  • Northwest Biotherapeutics: An Example Of Reform In The Drug Approval Process [View article]
    Indeed, and your citation has come on time also regarding Germany in this respect.
    Aug 22 11:51 AM | 1 Like Like |Link to Comment
  • Compugen Goes the Extra Mile in Drug Discovery [View article]
    Earnings was never a real issue in development-stage firms with outstanding technologies except in the minds that wish them to be. Here we are, the stock has doubled after two years of creativity without earnings. Plenty of examples exist, the most obvious and lucrative to investors is Pharmacyclics (PCYC) whose stock has gone from less than $10 to over $100 in the past two years based on a great drug not on earnings.
    Aug 22 11:45 AM | Likes Like |Link to Comment